Issar Pharmaceuticals Pvt. Ltd. (Issar) was established in the year 1995 by Mr.Ram Isanaka, one of the promoters of Shanta Biotech. Issar Pharma is a pioneer in the research and development of innovative peptide-based therapeutics, which focus on Solid Phase Peptide Synthesis. ISSAR ’s USFDA compliant R&D, with a state – of – the – art production facility of 62,000 Sft was established at Genome Valley, MN Park, Hyderabad, Telangana, India in 2012.

Since its inception, Issar Pharma has been working on development of new peptide based drugs to treat different health problems. After six years of committed research, Issar Pharma invented and commercialised India’s first ever indigenously developed new peptide molecule, Decapeptide, for the novel treatment of Vitiligo. This product was released into the market in 2004 under the product name Melgain®. Issar Pharma also invented and developed for the first time in the world its second peptide New Chemical Entity (NCE) which is first ever peptide based drug to treat burn wounds and microbial infection in India and world. This is going to be launched in Indian Market soon with the brand name of Xylentra™. The other molecules in pipeline are intended to be active against cancer, diabetic ulcers, HIV-AIDS, Acne, Psoriasis, Atopic Dermatitis, Inflammatory Bowel Disease, etc.


To be an innovative product developer and to produce safe, efficacious, quality products.



Our mission is to address the unmet health care needs by developing new peptide based drugs and make them available in affordable cost to mankind.